LATE-BREAKING RESEARCH: Practice Management Research
Abstract #LB03

Evaluation of the Reliability of 5-FU Elastomeric Pump in an Ambulatory Infusion Center

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Quan Li, PharmD, BCOP, BCPS, Clinical Coordinator, MedStar Washington Hospital Center, Washington, DC

Co-Author: Alice Beers, BSN, OCN, NPD-BC, MedStar Washington Hospital Center, Washington, DC

BACKGROUND: Continuous infusion of fluorouracil (5-FU) is often used in the treatment of gastrointestinal (GI) malignancies through an ambulatory infusion pump.1,2 However, the infusion rate of elastomeric pumps is affected by environmental and patient factors.3,4 Monitoring drug delivery by the pump is essential to treatment efficiency and drug safety.5 Visual inspection, as recommended in the package insert, is not reliable. A quantitative method to assess the delivery of 5-FU via an elastomeric pump is in great need. Recently, Cusano and colleagues showed the feasibility to monitor 5-FU delivery via Baxter elastomeric pump by comparing pump weights before and after infusion.6 However, more than 24% of the pumps had remaining fluid of >10%, suggesting insufficient delivery of the elastomeric pumps.6,7

OBJECTIVE: To evaluate the reliability of SMARTeZ elastomeric pump to deliver 5-FU, by measuring the percentage of pumps that deliver >90% of expected 5-FU dose at the end of 46 hours of infusion.

METHOD: This retrospective chart-review study included patients who were at least 18 years old, diagnosed with GI cancer and treated with intravenous 5-FU continuous infusion over 46 hours through elastomeric pump between April 1, 2021, and September 30, 2021. Pregnant females or patients younger than 18 years old were excluded. The primary end point was the reliability of the 5-FU elastomeric pump, measured by the percentage of elastomeric pumps delivering >90% of expected 5-FU doses. Secondary end points included the average percentage of 5-FU delivery of each pump, the average weight of empty, and full and returned empty pump.

RESULTS: A total of 24 patients and 117 pumps were included in the analysis. Overall, 95.7% of the patients received >90% of expected 5-FU dose. The average percentage of 5-FU delivery was 94.9% ± 7.3%. The average weight of empty, full, and returned pumps was 92.9 g ± 1.3 g, 335.1 g ± 1.5 g, and 105.4 g ± 17.7 g, respectively.

CONCLUSION: SMARTeZ elastomeric pumps were reliable to deliver 5-FU continuous infusion over 46 hours for patients with cancer.

  1. Sabbagh Dit Hawasli R, Barton S, Nabhani-Gebara S. Ambulatory chemotherapy: past, present, and future. J Oncol Pharm Pract. 2021;27:962-973.
  2. Backler C. Which ambulatory infusion pump is best for 5-FU? April 18, 2019. ONS Voice. https://voice.ons.org/news-and-views/which-ambulatory-infusion-pump-is-best-for-5-fu. Accessed July 31, 2021.
  3. Salman D, Biliune J, Kayyali R, et al. Evaluation of the performance of elastomeric pumps in practice: are we under-delivering on chemotherapy treatments? Curr Med Res Opin. 2017;33:2153-2159.
  4. Abe T, Matsuzaka K, Nakayama T, et al. Impact of air temperature and drug concentration on liquid emission from elastomeric pumps. J Pharm Health Care Sci. 2021;7:1. doi: 10.1186/s40780-020-00185-5.
  5. Institute for Safe Medication Practices. Accidental overdoses involving fluorouracil infusions. June 18, 2015. www.ismp.org/resources/accidental-overdoses-involving-fluorouracil-infusions. Accessed August 31, 2021.
  6. Cusano EL, Ali R, Sawyer MB, et al. Baxter elastomeric pumps: weighing as an alternative to visual inspection. J Oncol Pharm Pract. 2018;24:163-169.
  7. Chambers CR, Pabia M, Sawyer M, Tang PA. Baxter elastomeric pumps: feasibility of weight estimates. J Oncol Pharm Pract. 2017;23:429-435.
Related Items
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: